Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone.
Manno, D
; Ayieko, P; Ishola, D; Afolabi, MO; Rogers, B; Baiden, F; Serry-Bangura, A; Bah, OM; Köhn, B; Swaray, I; +14 more...Owusu-Kyei, K; Otieno, GT; Kowuor, D; Tindanbil, D; Smout, E; Robinson, C; Keshinro, B; Foster, J; Gallagher, K; Lowe, B; Douoguih, M; Leigh, B; Greenwood, B; Watson-Jones, D and
(2022)
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone.
Emerging Infectious Diseases, 28 (3).
pp. 734-738.
ISSN 1080-6040
DOI: 10.3201/eid2803.211496
; Ayieko, P; Ishola, D; Afolabi, MO; Rogers, B; Baiden, F; Serry-Bangura, A; Bah, OM; Köhn, B; Swaray, I; +14 more...Owusu-Kyei, K; Otieno, GT; Kowuor, D; Tindanbil, D; Smout, E; Robinson, C; Keshinro, B; Foster, J; Gallagher, K; Lowe, B; Douoguih, M; Leigh, B; Greenwood, B; Watson-Jones, D and
(2022)
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone.
Emerging Infectious Diseases, 28 (3).
pp. 734-738.
ISSN 1080-6040
DOI: 10.3201/eid2803.211496
We explored the association of Ebola virus antibody seropositivity and concentration with potential risk factors for infection. Among 1,282 adults and children from a community affected by the 2014-2016 Ebola outbreak in Sierra Leone, 8% were seropositive for virus antibodies but never experienced disease symptoms. Antibody concentration increased with age.
-
picture_as_pdf - Manno_etal_2022_Ebola-virus-glycoprotein-igg-seroprevalence.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution 4.0
Downloads